1,3,4-Thiadiazole Derivatives as VEGFR-2 Inhibitors and Its Molecular Insight for Cancer Therapy

Area of Science:

• Oncology
• Medicinal Chemistry
• Molecular Biology

Background:

• Vascular endothelial growth factor receptor-2 (VEGFR-2) is crucial for tumor growth, angiogenesis, and metastasis.
• Current VEGFR-2 inhibitors face challenges including resistance, toxicity, and lack of selectivity.
• The 1,3,4-thiadiazole (TDA) scaffold presents a promising structure for developing new anticancer agents.

Purpose of the Study:

• To review the role of VEGFR-2 in cancer.
• To explore the chemistry and VEGFR-2 inhibitory mechanisms of 1,3,4-TDA derivatives.
• To analyze structure-activity relationships (SAR) and guide the design of novel inhibitors.

Main Methods:

• Systematic literature review of 1,3,4-TDA based VEGFR-2 inhibitors published in the last decade.
• Analysis of 151 TDA derivatives, evaluating chemical space, SAR, selectivity, toxicity, and binding interactions.
• Examination of TDA scaffold's specific chemical features contributing to VEGFR-2 binding.

Main Results:

• 1,3,4-TDA derivatives demonstrate significant potential for VEGFR-2 inhibition.
• Key molecular interactions involving the TDA scaffold's motif and sulfur atom are critical for VEGFR-2 binding.
• Analysis identified specific substitution patterns and SAR trends influencing inhibitor efficacy and selectivity.

Conclusions:

• 1,3,4-TDA derivatives represent a valuable scaffold for developing next-generation VEGFR-2 inhibitors.
• These compounds offer a strategic advantage for designing more selective and less toxic anticancer therapies.
• Further research into TDA-based inhibitors can lead to improved anticancer drug candidates.